中文English
ISSN 1001-5256
CN 22-1108/R

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

《IgG4相关性疾病诊治中国专家共识》解读

周佳鑫 张文

周佳鑫,张文. 《IgG4相关性疾病诊治中国专家共识》解读[J]. 临床肝胆病杂志, 2021, 37(9): 2062-2065. DOI: 10.3969/j.issn.1001-5256.2021.09.012
引用本文: 周佳鑫,张文. 《IgG4相关性疾病诊治中国专家共识》解读[J]. 临床肝胆病杂志, 2021, 37(9): 2062-2065. DOI: 10.3969/j.issn.1001-5256.2021.09.012
ZHOU JX, ZHANG W. Interpretation of Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases[J]. J Clin Hepatol, 2021, 37(9): 2062-2065. DOI: 10.3969/j.issn.1001-5256.2021.09.012
Citation: ZHOU JX, ZHANG W. Interpretation of Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases[J]. J Clin Hepatol, 2021, 37(9): 2062-2065. DOI: 10.3969/j.issn.1001-5256.2021.09.012

《IgG4相关性疾病诊治中国专家共识》解读

DOI: 10.3969/j.issn.1001-5256.2021.09.012
基金项目: 

首都卫生发展科研专项基金 2020-2-4017

中国医学科学院中央级公益性科研院所基本科研业务费专项资金资助 2019XK320038

国家自然基金面上项目 82071839

详细信息
    通讯作者:

    张文,zhangwen91@sina.com

  • 中图分类号: R593.2

Interpretation of Chinese expert consensus on the diagnosis and treatment of IgG4-related diseases

Funds: 

The Capital's Funds for Health Improvement and Research 2020-2-4017

the Non-profit Central Research Institute Fund of Chinese Academy of Medical Sciences 2019XK320038

the National Natural Science Foundation of China 82071839

  • 摘要: IgG4相关性疾病(IgG4-RD)是一种以受累脏器慢性炎症伴纤维化为特征表现的免疫介导的疾病。近年来,我国学者对该病的认识逐渐深入,积累了较多的诊治经验,并于2020年在中国罕见病联盟和中华医学会风湿病学分会的平台上,由专家组制定了首个《IgG4相关性疾病诊治的中国专家共识》。该共识较全面概括了IgG4相关性疾病的诊治原则,为临床医生对该病的诊治提供了较好的依据。现就该指南的内容进行解读。

     

  • [1] KHOSROSHAHI A, WALLACE ZS, CROWE JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease[J]. Arthritis Rheumatol, 2015, 67(7): 1688-1699. DOI: 10.1002/art.39132.
    [2] ZHANG W, DONG LL, ZHU J, et al. Chinese expert consensus on the diagnosis and treatment of IgG4 related diseases[J]. Chin J Intern Med, 2021, 60(3): 192-206. DOI: 10.3760/cma.j.cn112138-20200803-00726.

    张文, 董凌莉, 朱剑, 等. IgG4相关性疾病诊治中国专家共识[J]. 中华内科杂志, 2021, 60(3): 192-206. DOI: 10.3760/cma.j.cn112138-20200803-00726.
    [3] STONE JH, KHOSROSHAHI A, DESHPANDE V, et al. Recommendations for the nomenclature of IgG4-related disease and its individual organ system manifestations[J]. Arthritis Rheum, 2012, 64(10): 3061-3067. DOI: 10.1002/art.34593.
    [4] KAMISAWA T, ZEN Y, PILLAI S, et al. IgG4-related disease[J]. Lancet, 2015, 385(9976): 1460-1471. DOI: 10.1016/S0140-6736(14)60720-0.
    [5] LIU Y, XUE M, WANG Z, et al. Salivary gland involvement disparities in clinical characteristics of IgG4-related disease: A retrospective study of 428 patients[J]. Rheumatology (Oxford), 2020, 59(3): 634-640. DOI: 10.1093/rheumatology/kez280.
    [6] LI W, CHEN Y, SUN ZP, et al. Clinicopathological characteristics of immunoglobulin G4-related sialadenitis[J]. Arthritis Res Ther, 2015, 17(1): 186. DOI: 10.1186/s13075-015-0698-y.
    [7] UMEHARA H, OKAZAKI K, MASAKI Y, et al. Comprehensive diagnostic criteria for IgG4-related disease (IgG4-RD), 2011[J]. Mod Rheumatol, 2012, 22(1): 21-30. DOI: 10.1007/s10165-011-0571-z.
    [8] WALLACE ZS, NADEN RP, CHARI S, et al. The 2019 American College of Rheumatology/European league against rheumatism classification criteria for IgG4-related disease[J]. Arthritis Rheumatol, 2020, 72(1): 7-19. DOI: 10.1002/art.41120.
    [9] HAMANO H, KAWA S, HORIUCHI A, et al. High serum IgG4 concentrations in patients with sclerosing pancreatitis[J]. N Engl J Med, 2001, 344(10): 732-738. DOI: 10.1056/NEJM200103083441005.
    [10] CARRUTHERS MN, KHOSROSHAHI A, AUGUSTIN T, et al. The diagnostic utility of serum IgG4 concentrations in IgG4-related disease[J]. Ann Rheum Dis, 2015, 74(1): 14-18. DOI: 10.1136/annrheumdis-2013-204907.
    [11] WANG Y, GUAN Z, GAO D, et al. The value of (18)F-FDG PET/CT in the distinction between retroperitoneal fibrosis and its malignant mimics[J]. Semin Arthritis Rheum, 2018, 47(4): 593-600. DOI: 10.1016/j.semarthrit.2017.07.011.
    [12] ZHANG J, CHEN H, MA Y, et al. Characterizing IgG4-related disease with 18F-FDG PET/CT: A prospective cohort study[J]. Eur J Nucl Med Mol Imaging, 2014, 41(8): 1624-1634. DOI: 10.1007/s00259-014-2729-3.
    [13] ZHAO Z, WANG Y, GUAN Z, et al. Utility of FDG-PET/CT in the diagnosis of IgG4-related diseases[J]. Clin Exp Rheumatol, 2016, 34(1): 119-125. http://www.ncbi.nlm.nih.gov/pubmed/26842851
    [14] DESHPANDE V, ZEN Y, CHAN JK, et al. Consensus statement on the pathology of IgG4-related disease[J]. Mod Pathol, 2012, 25(9): 1181-1192. DOI: 10.1038/modpathol.2012.72.
    [15] ARORA K, RIVERA M, TING DT, et al. The histological diagnosis of IgG4-related disease on small biopsies: Challenges and pitfalls[J]. Histopathology, 2019, 74(5): 688-698. DOI: 10.1111/his.13787.
    [16] CAMPBELL SN, RUBIO E, LOSCHNER AL. Clinical review of pulmonary manifestations of IgG4-related disease[J]. Ann Am Thorac Soc, 2014, 11(9): 1466-1475. DOI: 10.1513/AnnalsATS.201403-128FR.
    [17] WANG ZQ, LIU YY, ZHANG X, et al. Analysis of the clinical features and misdiagnosis reasons of 17 patients misdiagnosed with IgG4-related disease[J]. J Peking Univ(Health Sci), 2019, 51(6): 1025-1031. DOI: 10.19723/j.issn.1671-167X.2019.06.008.

    王子乔, 刘燕鹰, 张霞, 等. 17例误诊为IgG4相关疾病患者的临床特点及误诊原因分析[J]. 北京大学学报(医学版), 2019, 51(6): 1025-1031. DOI: 10.19723/j.issn.1671-167X.2019.06.008.
    [18] HONG X, LI W, XIE XY, et al. Differential diagnosis of IgG4-related sialadenitis, primary Sjögren syndrome, and chronic obstructive submandibular sialadenitis[J]. Br J Oral Maxillofac Surg, 2017, 55(2): 179-184. DOI: 10.1016/j.bjoms.2016.10.021.
    [19] BAI Z, CHEN Y, CHEN X, et al. A medical mirroring: Chronic myelomonocytic leukemia mimicking immunoglobulin G4-related disease[J]. Am J Transl Res, 2019, 11(7): 4561-4567. http://www.researchgate.net/publication/335099953_A_medical_mirroring_chronic_myelomonocytic_leukemia_mimicking_immunoglobulin_G4-related_disease
    [20] WALLACE ZS, KHOSROSHAHI A, CARRUTHERS MD, et al. An international multispecialty validation study of the IgG4-related disease responder index[J]. Arthritis Care Res (Hoboken), 2018, 70(11): 1671-1678. DOI: 10.1002/acr.23543.
    [21] ZHANG W, STONE J. Management of IgG4 related disease[J]. The Lancet Rheumatol, 2019, 1(1): e55-e65. DOI: https://doi.org/ 10.1016/S2665-9913(19)30017-7.
    [22] MIKI M, FUJIMORI N, OONO T, et al. Relapse patterns and predictors of IgG4-related diseases involved with autoimmune pancreatitis: A single-center retrospective study of 115 patients[J]. J Dig Dis, 2019, 20(3): 152-158. DOI: 10.1111/1751-2980.12708.
    [23] BACKHUS J, SEUFFERLEIN T, PERKHOFER L, et al. IgG4-related diseases in the gastrointestinal tract: Clinical presentation, diagnosis and treatment challenges[J]. Digestion, 2019, 100(1): 1-14. DOI: 10.1159/000492814.
    [24] OKAZAKI K, UCHIDA K. Current perspectives on autoimmune pancreatitis and IgG4-related disease[J]. Proc Jpn Acad Ser B Phys Biol Sci, 2018, 94(10): 412-427. DOI: 10.2183/pjab.94.027.
    [25] OKAZAKI K, CHARI ST, FRULLONI L, et al. International consensus for the treatment of autoimmune pancreatitis[J]. Pancreatology, 2017, 17(1): 1-6. DOI: 10.1016/j.pan.2016.12.003.
    [26] KAMISAWA T, NAKAZAWA T, TAZUMA S, et al. Clinical practice guidelines for IgG4-related sclerosing cholangitis[J]. J Hepatobiliary Pancreat Sci, 2019, 26(1): 9-42. DOI: 10.1002/jhbp.596.
    [27] EBBO M, DANIEL L, PAVIC M, et al. IgG4-related systemic disease: Features and treatment response in a French cohort: Results of a multicenter registry[J]. Medicine (Baltimore), 2012, 91(1): 49-56. DOI: 10.1097/MD.0b013e3182433d77.
    [28] RAINA A, YADAV D, KRASINSKAS AM, et al. Evaluation and management of autoimmune pancreatitis: Experience at a large US center[J]. Am J Gastroenterol, 2009, 104(9): 2295-2306. DOI: 10.1038/ajg.2009.325.
    [29] WU Q, CHANG J, CHEN H, et al. Efficacy between high and medium doses of glucocorticoid therapy in remission induction of IgG4-related diseases: A preliminary randomized controlled trial[J]. Int J Rheum Dis, 2017, 20(5): 639-646. DOI: 10.1111/1756-185X.13088.
    [30] WALLACE ZS, MATTOO H, MAHAJAN VS, et al. Predictors of disease relapse in IgG4-related disease following rituximab[J]. Rheumatology (Oxford), 2016, 55(6): 1000-1008. DOI: 10.1093/rheumatology/kev438.
    [31] MASAMUNE A, NISHIMORI I, KIKUTA K, et al. Randomised controlled trial of long-term maintenance corticosteroid therapy in patients with autoimmune pancreatitis[J]. Gut, 2017, 66(3): 487-494. DOI: 10.1136/gutjnl-2016-312049.
    [32] OMAR D, CHEN Y, CONG Y, et al. Glucocorticoids and steroid sparing medications monotherapies or in combination for IgG4-RD: A systematic review and network meta-analysis[J]. Rheumatology (Oxford), 2020, 59(4): 718-726. DOI: 10.1093/rheumatology/kez380.
    [33] WANG Y, LI K, GAO D, et al. Combination therapy of leflunomide and glucocorticoids for the maintenance of remission in patients with IgG4-related disease: A retrospective study and literature review[J]. Intern Med J, 2017, 47(6): 680-689. DOI: 10.1111/imj.13430.
    [34] YUNYUN F, YU C, PANPAN Z, et al. Efficacy of Cyclophosphamide treatment for immunoglobulin G4-related disease with addition of glucocorticoids[J]. Sci Rep, 2017, 7(1): 6195. DOI: 10.1038/s41598-017-06520-5.
    [35] ZHANG P, GONG Y, LIU Z, et al. Efficacy and safety of iguratimod plus corticosteroid as bridge therapy in treating mild IgG4-related diseases: A prospective clinical trial[J]. Int J Rheum Dis, 2019, 22(8): 1479-1488. DOI: 10.1111/1756-185X.13633.
    [36] HONG X, ZHANG YY, LI W, et al. Treatment of immunoglobulin G4-related sialadenitis: Outcomes of glucocorticoid therapy combined with steroid-sparing agents[J]. Arthritis Res Ther, 2018, 20(1): 12. DOI: 10.1186/s13075-017-1507-6.
    [37] CARRUTHERS MN, TOPAZIAN MD, KHOSROSHAHI A, et al. Rituximab for IgG4-related disease: A prospective, open-label trial[J]. Ann Rheum Dis, 2015, 74(6): 1171-1177. DOI: 10.1136/annrheumdis-2014-206605.
    [38] XIN L, MENG QQ, HU LH, et al. Prediction and management for relapse of type 1 autoimmune pancreatitis after initial steroid treatment: A long-term follow-up from China[J]. Pancreas, 2018, 47(9): 1110-1114. DOI: 10.1097/MPA.0000000000001147.
    [39] LIU Y, ZENG Q, ZHU L, et al. Relapse predictors and serologically unstable condition of IgG4-related disease: A large Chinese cohort[J]. Rheumatology (Oxford), 2020, 59(8): 2115-2123. DOI: 10.1093/rheumatology/kez669.
    [40] PENG Y, LI JQ, ZHANG PP, et al. Clinical outcomes and predictive relapse factors of IgG4-related disease following treatment: A long-term cohort study[J]. J Intern Med, 2019, 286(5): 542-552. DOI: 10.1111/joim.12942.
    [41] HART PA, KAMISAWA T, BRUGGE WR, et al. Long-term outcomes of autoimmune pancreatitis: A multicentre, international analysis[J]. Gut, 2013, 62(12): 1771-1776. DOI: 10.1136/gutjnl-2012-303617.
    [42] PENG L, ZHANG P, LI J, et al. IgG4-related aortitis/periaortitis and periarteritis: A distinct spectrum of IgG4-related disease[J]. Arthritis Res Ther, 2020, 22(1): 103. DOI: 10.1186/s13075-020-02197-w.
  • 加载中
计量
  • 文章访问数:  108
  • HTML全文浏览量:  19
  • PDF下载量:  65
  • 被引次数: 0
出版历程
  • 收稿日期:  2021-08-16
  • 修回日期:  2021-08-16
  • 分享
  • 用微信扫码二维码

    分享至好友和朋友圈

目录

    /

    返回文章
    返回